Table 3 Postoperative adjuvant chemotherapy related adverse reactions
Adverse Event | CTCAE v5.0 grade 1–2 | CTCAE v5.0 grade 3–4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
GP (n = 39) | mFOLFIRINOX (n = 29) | S−1 (n = 51) | Z | P | GP (n = 39) | mFOLFIRINOX (n = 29) | S−1 (n = 51) | Z | P | |
Nausea | 19 48.7% | 15 51.7% | 24 47.1% | 0.161 | 0.923 | 10 25.6% | 5 17.2% | 8 15.7% | 1.512 | 0.470 |
Diarrhea | 17 43.6% | 13 44.8% | 25 49.0% | 0.292 | 0.864 | 5 12.8% | 3 10.3% | 5 9.8% | 0.220 | 0.896 |
Rash | 18 46.2% | 8 27.6% | 22 43.1% | 2.674 | 0.263 | 2 5.1% | 3 10.3% | 3 5.9% | 0.822 | 0.663 |
Hand-foot syndrome | 12 30.8% | 8 27.6% | 22 43.1% | 2.478 | 0.290 | 5 12.8% | 4 13.8% | 4 7.8% | 0.887 | 0.642 |
Fatigue | 13 33.3% | 11 37.9% | 21 41.2% | 0.578 | 0.749 | 5 12.8% | 5 17.2% | 4 7.8% | 1.635 | 0.441 |
Leucopenia | 13 33.3% | 13 44.8% | 20 39.2% | 0.938 | 0.625 | 4 10.3% | 4 13.8% | 7 13.7% | 0.291 | 0.865 |
Anemia | 9 23.1% | 10 34.5% | 9 17.6% | 2.919 | 0.232 | 7 17.9% | 4 13.8% | 6 11.8% | 0.698 | 0.705 |
Thrombocytopenia | 14 35.9% | 9 31.0% | 11 21.6% | 2.337 | 0.311 | 2 5.1% | 1 3.4% | 3 5.9% | 0.230 | 0.892 |
ALT elevation | 7 17.9% | 12 41.4% | 7 13.7% | 8.797 | 0.012 | 4 10.3% | 4 13.8% | 5 9.8% | 0.329 | 0.848 |
AST elevation | 6 15.4% | 12 41.4% | 8 15.7% | 8.567 | 0.014 | 3 7.7% | 0 0.0% | 5 9.8% | 2.921 | 0.232 |
TBIL elevation | 7 17.9% | 14 48.3% | 14 27.5% | 7.534 | 0.023 | 4 10.3% | 0 0.0% | 2 3.9% | 3.888 | 0.143 |
Proteinuria | 10 25.6% | 12 41.4% | 13 25.5% | 2.645 | 0.266 | 0 0.0% | 2 6.9% | 2 3.9% | 2.522 | 0.283 |
Hematuresis | 5 12.8% | 11 37.9% | 9 17.6% | 6.927 | 0.031 | 3 7.7% | 0 0.0% | 1 2.0% | 3.569 | 0.168 |
Creatinine elevation | 7 17.9% | 12 41.4% | 10 19.6% | 6.052 | 0.049 | 4 10.3% | 1 3.4% | 2 3.9% | 2.012 | 0.366 |